Navigation Links
Vaccinex, Inc. Initiates Clinical Trial of Novel Therapeutic Antibody in Cancer Patients With Advanced Solid Tumors
Date:1/4/2011

ROCHESTER, N.Y., Jan. 4, 2011 /PRNewswire/ -- Vaccinex, Inc. announced today that it has received clearance from FDA and will initiate a Phase 1 clinical trial to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of therapeutic antibody candidate VX15/2503 in cancer patients with advanced solid tumors.

(Logo: http://photos.prnewswire.com/prnh/20101101/NY92716LOGO)

VX15/2503 is a novel humanized antibody that blocks the activity of semaphorin 4D (SEMA4D).  It is the first of two of the Company's therapeutic antibodies expected to begin clinical trials this year. "Advancing VX15 into the clinical stage of development is an exciting achievement for Vaccinex, and a testament to the experience and outstanding capabilities of our research and development teams," said Ray Watkins, Senior Vice President and Chief Operating Officer of the company.

"SEMA4D is an exciting therapeutic target with remarkable biological properties relevant to several disease processes," said Dr. Maurice Zauderer, President and Chief Executive Officer of Vaccinex.  As reflected in its name, semaphorin, the molecule guides the activation and movement of different cell types in different ways.  For example, SEMA4D promotes migration of tumor cells that metastasize to new locations as well as the outgrowth of cells that form new blood vessels required to provide nutrients and energy to tumors.  It is anticipated that, by blocking this signal, the anti-SEMA4D antibody will both inhibit the growth of primary tumors and limit metastases to new sites.  "This is important," Dr. Zauderer said, "because if tumors did not metastasize, then surgeons could cure cancer."  In other tissues and disease processes, for example damage to neurons in demyelinating diseases such as multiple sclerosis (MS), the same semaphorin has an opposite effect on outgrowth of cells, preventing the regeneration and remyelination of damaged neurons.  In this case, Dr. Zauderer said, "The VX15/2503 antibody has the potential to be a radical new approach to treatment of MS, acting both as an anti-inflammatory to protect against disease progression but also promoting healing of damaged tissue."  Vaccinex plans to initiate a second trial of VX15/2503 for MS later this year.  

About Vaccinex, Inc.

Founded in 1997 and located in Rochester, NY, Vaccinex, Inc. is a privately held biotechnology company engaged in the discovery and development of human therapeutic monoclonal antibodies and vaccines to treat serious diseases with unmet needs.   http://www.vaccinex.com/.

Press Contact

Raymond E. Watkins, Chief Operating Officer, 585.271.2700 (x-105)

e-mail: rwatkins@vaccinex.com


'/>"/>
SOURCE Vaccinex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Vaccinex, Inc. Awarded Three Qualifying Therapeutic Discovery Project (QTDP) Grants Under the Patient Protection and Affordable Care Act of 2010 (PPACA)
2. Tolerx Initiates Phase 1 Clinical Trial of TRX518, a First-in-Class anti-GITR Antibody for the Treatment of Cancer
3. Pfizer Stops Clinical Trials of Thelin® and Initiates Voluntary Product Withdrawal in the Interest of Patient Safety
4. GeNO LLC Initiates Phase 2 Trial For Nitric Oxide Delivery System
5. SPECTRAL INITIATES U.S. PIVOTAL TRIAL OF TORAYMYXIN™ IN SEPTIC SHOCK
6. Circassia Initiates Phase II Trials of Novel Grass and Ragweed Allergy Therapies and Advances Phase III Plans for cat Allergy T-Cell Vaccine
7. Cylene Initiates Phase I Trial in Multiple Myeloma With CX-4945 Inhibitor of CK2 and Closes Accompanying Financing
8. Xenon Pharmaceuticals Initiates a Phase 2 Clinical Trial in Post Herpetic Neuralgia (PHN) for Topical XEN402.
9. Pieris Initiates Phase I Clinical Trial for Lead Anticalin Compound
10. Onyx Pharmaceuticals Initiates Phase 1 Study of Oral Proteasome Inhibitor in Advanced Solid Tumors
11. NewLink Initiates Pivotal Phase 3 Clinical Trial of HyperAcute(R)-Pancreas Immunotherapy for Resected Pancreatic Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... , Feb. 4, 2016 Sinovac Biotech ... a leading provider of biopharmaceutical products in ... of its board of directors received on February 4, ... 2016, from a consortium comprised of PKU V-Ming ( ... Biomedicine Co., Ltd., CICC Qianhai Development ( Shenzhen ...
(Date:2/3/2016)... , Feb. 3, 2016  Discovery Laboratories, Inc. ... on developing aerosolized KL4 surfactant therapies for respiratory ... has approved an inducement award as a component ... its newly appointed President and Chief Executive Officer.  ... Committee on February 1, 2016 and granted as ...
(Date:2/3/2016)... ... February 03, 2016 , ... Aerocom, a world-leading supplier ... the North American healthcare market. , Aerocom Healthcare, LLC will be based in ... will provide new pneumatic tube systems or expand existing systems within the U.S. ...
(Date:2/3/2016)... , Feb. 3, 2016  Today, Symphony Technology ... AlphaImpactRx , a leading provider of primary research ... to IMS Health , a global information and ... offerings, capabilities and technologies will be integrated into IMS ... global primary market research capabilities. ...
Breaking Biology Technology:
(Date:2/1/2016)... 1, 2016  Wocket® smart wallet ( www.wocketwallet.com ) announces the launch ... Joey Fatone . Las Vegas , where Joey ... --> Las Vegas , where Joey appeared at the ... new video ad was filmed at the Consumer Electronics Show (CES2016) in ... booth to meet and greet fans. --> ...
(Date:1/25/2016)... -- Glencoe Software, the world-leading supplier of image data management ... the data management solution OMERO Plus for the newly ... Photo - http://photos.prnewswire.com/prnh/20160125/325328LOGO ... Phenotypic analysis measures the characteristics and behavior of cells, ... such as health and disease, the presence or absence ...
(Date:1/20/2016)... -- A market that just keeps on growing. Molecular ... in genomics knowledge. Learn all about it in this ... dynamic trends are pushing market growth and company valuations. ... - pathogen evolution - next generation sequencing - emergence ... of the role of genetic material in Disease and ...
Breaking Biology News(10 mins):